Michael Miller

Michael J. Miller, RPh, DrPH, FAPhA

Research Scientist II



2004 – Doctor of Public Health, Graduate School of Public Health, University of Pittsburgh
1995 – Master of Science in Pharmacy Administration, College of Pharmacy, The University of Arizona
1988 – Bachelor of Science Degree in Pharmacy, School of Pharmacy, University of Pittsburgh

Professional affiliations:

Academy of Health Services Research
American Pharmacists Association
American Society of Health System Pharmacy

Dr. Miller has been a pharmacist for more than 30 years in clinical, management and research environments across private, government and academic sectors. He holds Bachelor and Master of Science degrees in pharmacy, a Doctor of Public Health degree, and is a Fellow of the American Pharmacists Association. He has taught courses related to design, analysis and interpretation of research studies to ensure appropriate application to healthcare decision-making in professional and graduate programs. Most recently at Texas A&M University, he taught content related to the US health care system and the social and behavioral aspects of the medication use process. Using both primary and secondary data, he has focused study on refining methods to measure and identify those at risk for low health literacy, evaluating the literacy-sensitivity of pharmacy processes and environments, and identifying interventions that improve health literacy and ensure optimal medication use and risk communication.

He has served as a Special Government Employee (SGE) Consultant to the FDA/CDER Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. His primary areas of clinical interest include cardiovascular-related disease, rheumatology, depression, and infectious disease. Past partners for his research initiatives include the Iowa Health System, the American Society of Health System Pharmacists Research and Education Foundation, the University of Alabama – Birmingham Deep South Arthritis and Musculoskeletal Center for Education and Research on Therapeutics (DSAM CERTs), and First Databank. Current research partners include Johns Hopkins Medicine and Pfizer, Inc.

For a full list of publications, please see Dr. Miller’s Curriculum Vitae

  1. Miller MJ, Watson ES, Horberg MA, Bhatia M, Tripuraneni BR, McCarthy RJ. Patient Experience After Modifying Visit Delivery During the COVID-19 Pandemic. American Journal of Managed Care. 2021;27(2):e54-e63.
  2. Miller MJ, Jou T, Danila MI, Mudano AS, Rahn EJ, Outman RC, Saag KG. Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use. Res Social Adm Pharm. 2020, available online September 20, 2020.
  3. Adami G, Saag KG, Mudano AS, Rahn EJ, Wright NC, Outman RC, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Ladores S, Curtis JR, Danila MI. Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. Osteoporosis International. 2020; 31:1283-1290.
  4. Desselle SP, Chen AM, Amin M, Aslani P, Dawoud D, Miller MJ, Nørgaard LS. Generosity, collegiality, and scientific accuracy when writing and reviewing original research. Res Social Adm Pharm. 2020;16(2):261-265. Available online May 12, 2019.
  5. Desselle S, Amin M, Aslani P,  Chen A, Dawoud D, Miller M, Norgaard L. “Moving the needle—what does RSAP look for and what does it aim to do?” Res Social Adm Pharm. 2019 Jan;15(1):1-2. 2018.10.026. Epub 2018 Oct 22.
  6. Miller M, Nutbeam D. “Advancing the international understanding of health literacy in pharmacy: Current trend and future directions.” Res Social Admin Pharm. 2018;14:v-vi.
  7. Danila M, Outman R, Rahn E, Mudano A, Redden D, Li P, Allison J,  Anderson F, Wyman A, Greenspan S, LaCroix A, Nieves J, Silverman S, Siris E, Watts N, Miller M, Curtis J, Warriner A, Wright N, Saag K. “Evaluation of a Multi-modal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis: A Randomized Clinical Trial.” J Bone Miner Res. 2018;33(5):763–772.
  8. Stirratt M, Curtis J, Danila M, Hansen R, Miller M, Gakumo C. “Advancing the Science and Practice of Medication Adherence. “J Gen Intern Med.  2018;33:216-222.
  9. Bulkley C, Miller M, Draugalis J, Nussbaum B, Bush C. “Preparing Advanced Practice Pharmacists for Research: Needs Assessment and Training Program Development.” Am J Health-Syst Pharm. 2017;74 (23):1986-1995.
  10. Van Den Bogert C, Miller M, Cobaugh D, Chen L, Allison J, Saag K. “Screening questions for nonsteroidal anti-inflammatory drug risk knowledge.” J Patient Saf. 2017;13(4):217-222. doi: 10.1097/PTS.0000000000000143.
  11. David C, O’Neal K, Miller M, Johnson J, Lloyd A. “A literacy-sensitive approach to improving antibiotic understanding in a community-based setting.” Int J Pharm Pract. 2017;25(5):395-398. doi:10.1111/ijpp.12332.
  12. Thiessen K, Lloyd A, Miller M, Homco, J, O’Neal K, Gildon B. “Infection. Assessing guideline-concordant prescribing for community-acquired pneumonia.” Int J Clin Pharm. 2017;39(4):674–678. doi: 10.1007/s11096-017-0489-4.
  13. Weech-Maldonado R, Miller M, Lord J. “The Relationships among Socio-Demographics, Perceived Health, and Happiness.” Applied Research in Quality of Life. 2017;12(2):289-302. doi 10.1007/s11482-017-9517-8.
  14. Miller M, Burns C, Kapusnik-Uner J, Carreno R, Matuszewski K. “Depression Screening for Medications with Mental Health Risk. Depression Screening for Prescribed Medications with Mental Health Risk: Considerations for Clinical Decision Support, Workflow Redesign, and Health Information Exchange Arrangements.” Res Social Adm Pharm. 2017;13(3):485-493.
  15. Bulkley C, Miller M, Draugalis J. “Developing and improving residency research training.” Am J Health-Syst Pharm. 2017;74:152-61. DOI: 10.2146/ajhp150797.
  16. Houser S, Au D, Miller M, Chen L, Outman R, Ray M, Saag K, Weech-Maldonado R. “Socio-Demographic Differences in Risk Information Seeking Sources for Non-Steroidal Anti-inflammatory Drugs (NSAIDS).”  International Journal of Medical Informatics. 2016; 94:222-227
  17. Miller M, Weech-Maldonado R, Outman R, Ray M, Gary L, Chen L, Cobaugh D, Allison J, Saag K. “Evaluating the Effectiveness of a Patient Storytelling DVD Intervention to Encourage Physician-Patient Communication About Nonsteroidal Anti-Inflammatory Drug (NSAID) Use.” Patient Educ Couns. 6/16/2016.
  18. Danila M, Outman R, Rahn E, Mudano A, Thomas T, Redden D, Allison J, Anderson F, Anderson J, Cram P, Curtis J, Fraenkel L, Greenspan S, LaCroix A, Majumdar S, Miller M, Nieves J, Safford M, Silverman S, Siris E, Solomon D, Warriner A, Watts N, Yood R, Saag K. “A Multi-Modal Intervention for Activating Patients at Risk for Osteoporosis (APROPROS): Rationale, Design, and Uptake of Online Study Intervention Material.” Contemporary Clinical Trials Communications. 2016; 4: 14-24.
  19. Capino A, Miller J, Hughes K, Miller M, Johnson P. “Caregiver perception, self-efficacy, and knowledge of methadone tapers for children with iatrogenic opioid abstinence syndrome.” J Pharm Technol. 2015; 1-12. DOI: 10.1177/8755122515622030 [original research].
  20. Downes J, O’Neal K, Miller M, Johnson J, Gildon B, Weisz M. “Identifying opportunities to improve medication management in transitions of care.” Am J Health Syst Pharm. 2015; 72(17 Suppl 2):S58-69.
  21. Mittal M, Harrison D, Thompson D, Miller M, Farmer K, Ng Y. “An Evaluation of Three Statistical Estimation Methods for Assessing Health Policy Effects on Prescription Drug Claims.” Res Social Adm Pharm. Published online 4/3/2015. doi:10.1016/j.sapharm.2015.03.004.
  22. Cobaugh D, Miller M, Pham T, Krenzelok E. “Risk of Major Morbidity and Death in Older Adults with Suicidal Intent: A Cross –Sectional Analysis from the National Poison Data System, 2000-2009.” J Am Geriatr Soc. 2015;63:501-507.
  23. Kim M, Lloyd A, Condren M, Miller M. “Beyond Antibiotic Selection: Concordance with the IDSA Guidelines for Uncomplicated Urinary Tract Infections.” Infection. Published online 7/18/2014. DOI 10.1007/s15010-014-0659-4.
  24. Miller M, Allison J, Cobaugh D, Ray M, Saag K. “A Group Randomized Trial of Shared Decision-Making for Nonsteroidal Antiinflammatory Drug Risk Awareness: Primary Results and Lessons Learned.” J Eval Clin Pract. Published online 6/11/2014.
  25. Mittal M, Harrison D, Miller M, Farmer K, Thompson D, Ng Y. “Have antiepileptic drug prescription claims changed following the FDA suicidality warning? An evaluation in a state Medicaid program.” Epilepsy Behav. 2014;34:109-115.
  26. Schupbach R, Sparrow N, Harrison D, Miller M. “Participant Perspectives from the Indian Health Service Anticoagulation Training Program.” Int J Clin Pharm. 2013;35:1091-8.
  27. Mittal M, Harrison D, Miller M, Brahm N. “National Antidepressant Prescribing in Children and Adolescents with Mental Health Disorders after a FDA Boxed Warning.” Res Social Adm Pharm. Published online 20 November 2013.
  28. Winchester B, Watkins S, Brahm N, Harrison D, Miller M. “Mental Health Treatment Associated with Community-Based Depression Screening: Considerations for Planning Multidisciplinary Collaborative Care.” Ann Pharmacother. 2013;47:797-804.
  29. Pham T, Miller M, Harrison D, Lloyd A, Crosby K, Johnson J. “Cardiovascular Disease and Nonsteroidal Anti-inflammatory Drug Prescribing In the Midst of Evolving Guidelines.” J Eval Clin Pract. 2013;19:1026-1034.
  30. Schupbach R, Bousum J, Miller M. “Demonstration of Anticoagulation Patient Self-testing Feasibility at an Indian Health Service Facility: A Case Series Analysis.” Pharmacy Practice. 2013; 11(1): 30-37.
  31. Miller M. “Pharmacy efforts in support of the National Action Plan to Improve Health Literacy.” Res Social Adm Pharm. 2013;9:497.
  32. O’Neal K, Crosby K, Miller M, Murray K, Condren M. “Assessing health literacy practices in a community pharmacy environment: Experiences using the AHRQ Pharmacy Health Literacy Assessment Tool.” Res Social Adm Pharm. 2013;9:564-596.
  33. Collum J, Marcy T, Stevens E, Burns C, Miller M. “Exploring patient expectations for pharmacist-provided literacy-sensitive communication.” Res Social Adm Pharm.  2013;9:626-632.
  34. Wang L, Miller M, Schmitt M, Wen F. “Assessing readability formula differences with written health information materials: application, results, and recommendations.” Res Social Adm Pharm. 2013;9:503-516.
  35. Schmitt M, Miller M, Harrison D, Farmer K, Allison J, Cobaugh D, Saag K. “Communicating Non-Steroidal Anti-Inflammatory Drug Risks: Verbal Counseling, Written Medicine Information, and Patients’ Risk Awareness.” Patient Educ Couns. 2011; 83:391-397.
  36. Miller M, Abrams M, Earles B, Phillips K, McCleeary E. “Improving Patient-Provider Communication for Patients Having Surgery: Patient Perceptions of a Revised Health Literacy-Based Consent Process.” J Patient Saf. 2011;7:30-38.
  37. Rovers J, Miller M, Koenigsfeld C, Haack S, Hegge K, McCleeary E. “A guided interview process to improve student pharmacists’ identification of drug therapy problems.” Am J Pharm Educ. 2011;75(1) Article 16.
  38. Harrison D, Miller M, Schmitt M, Touchet B. “Variations in the Probability of Depression Screening at Community-Based Physician Practice Visits.” Prim Care Companion J Clin Psychiatry. 2010;12(5):e1-e8.
  39. Schmitt M, Miller M, Harrison D, Touchet B. “Relationship of Depression Screening to Physician Office Visit Duration in a National Sample.” Psychiatr Serv. 2010; 61:1126–1131.
  40. Miller M, Allison J, Schmitt M, Ray M, Funkhouser E, Cobaugh D, Saag K, LaCivita C. “Using Single-item Health Literacy Screening Questions to Identify Patients Who Read Written Non-steroidal Anti-Inflammatory Medicine Information Provided at Pharmacies.” J Health Commun. 2010;15:413-427.
  41. Miller M, Schmitt M, Allison J, Cobaugh D, Ray M, Saag K. “The Role of Health Literacy and Written Medicine Information in Non-Steroidal Anti-inflammatory Drug (NSAID) Risk Awareness.” Ann Pharmacother. 2010;44:274-284.
  42. Angner E, Miller M, Ray M, Saag K, Allison J. “Health Literacy and Happiness: A Community-Based Study.” Soc Indic Res. 2010; 95:325–338
  43. LaCivita C, Funkhouser E, Miller M, Ray M, Saag K, Kiefe C, Cobaugh D, Allison J. “Patient Reported Communications with Pharmacy Staff at Community Pharmacies: The Alabama NSAID Patient Safety Study, 2005-2007.” J Am Pharm Assoc. 2009;49:e110–e117. doi: 10.1331/JAPhA.2009.09005.
  44. Miller M, DeWitt J, McCleeary E, O’Keefe K. “Application of the Cloze Procedure to Evaluate Comprehension and to Demonstrate Rewriting of Pharmacy Educational Materials.” Ann Pharmacother. 2009;43:650-657.
  45. Miller M, Abrams M, McClintock B, Cantrell M, Dossett C, McCleeary E, McGee M, O’Keefe K, Sager E. “Promoting Health Communication Between the Community-Dwelling Well-Elderly and Pharmacists: The Ask Me 3 Program.” J Am Pharm Assoc. 2008; 48:784-792
  46. Wall G, Krypel L, Miller M, Rees D. “A Pilot Study of Complementary and Alternative Medicine Use in Patients with Fibromyalgia Syndrome.” Pharmacy Practice. 2007(5(4):185-190.
  47. Miller M, Degenholtz H, Gazmararian J, Lin C, Ricci E, Sereika S. “Identifying Elderly at Greatest Risk of Inadequate Health Literacy: A Predictive Model for Population Health Decision-makers.” Res Social Adm Pharm. 2007; 3(1):70-85.
  48. Gazmararian J, Kripalani S, Miller M, Echt K, Ren J, Rask K. “Factors Associated with Medication Refill Adherence in Cardiovascular-related Diseases: A Focus on Health Literacy.” J Gen Intern Med. 2006; 21:1215-1221.
  49. Degenholtz H, Miller M, Kane R, Cutler L, Kane R. “Developing a Typology of Nursing Home Environments.” J Hous Elderly. 2006; 20(1/2):5-30
  50. Cutler L, Kane R, Degenholtz H, Miller M, Grant L. “Assessing and Comparing Physical Environments for Nursing Home Residents: Using New Tools for Greater Research Specificity.” Gerontologist. 2006; 46(1):42-51.
  51. Miller M, Desselle S. “Employee Knowledge of a Managed Pharmacy Benefit in a Large Employer.” Manag Care Interface. 2005; 18(1):33-42.
  52. Degenholtz H, Thomas S, Miller M. “Race and the intensive care unit: Disparities and Preferences for End of Life Care.” Crit Care Med. 2003; 31(5, Supplement):S373-S378.
  53. Erstad B, Camamo J, Miller M, Webber A, Fortune J.  “Impacting Cost and Appropriateness of Stress Ulcer Prophylaxis at a University Medical Center.”  Crit Care Med. 1997; 25(10):1678-1684.
  54. Miller M, Draugalis J, Ortmeier B, Leischow S.  “A Retrospective Analysis of the Costs and Consequences of a Tobacco Cessation Program for Active Duty Service Members.”  Mil Med. 1996; 161; 7:420-424.
  55. Miller M, Ortmeier B.  “Factors Influencing the Delivery of Pharmacy Services.”  Am Pharm. 1994; NS35; 1:39-45.
  1. Addressing Medication Safety from the Pediatric Primary Care Perspective
    This research proposes to inform the development of an evidence-based intervention for primary care practices to promote and improve medication safety in households with children ≤19 years of age by:
    • Assessing potential and realized risk for injury and identify high yield areas for safety counseling by describing the medications most commonly prescribed to children <19 years in primary care practices and their household members in terms of hazardousness, and cases of medically attended poisoning events, among a sample of socioeconomically, racial/ethnically diverse patients identified by review of electronic medical records (EMR) of two large health systems [Johns Hopkins Medicine (JHM) and Kaiser Permanente Mid-Atlantic States (KPMAS)].
    The Kaiser Permanente and Johns Hopkins Medicine Research Collaboration Committee (RCC) Pilot Projects
    Role: Co-Investigator
  2. Development, Validation, and Testing of an Interoperable Predictive Model to Estimate Inadequate Health Literacy
    This research proposes to develop a method to identify patients at the highest risk for suboptimal health literacy by:
    • Utilizing responses to previously collected health literacy screening questions from a large database (the KP Research Bank (KPRB)) and universally collected clinical information from the Epic-based KP HealthConnect (KPHC) to develop and validate a predictive model for health literacy.
    • Exporting and testing the interoperability of the predictive model using data from the Epic-based Johns Hopkins Medicine and Health System (JHMHS).
    The Kaiser Permanente and Johns Hopkins Medicine Research Collaboration Committee (RCC) Pilot Projects
    Role: Principal Investigator
  3. Examining and Optimizing Adoption of Digital Mental Health Applications Across Health Systems
    Capitalizing on the unique differences between Kaiser Permanente Mid-Atlantic States (KPMAS) and Johns Hopkins Medicine and Health System (JHMHS) related to stages of adoption of digital mental health applications, this project seeks to better understand end-users to inform the development of a clinician user guide that can be applied across different health-system platforms by:
    • Developing clinician and patient profiles from experienced users that describe prescribing and use of digital mental health applications using existing electronic health record data and end-user surveys.
    • Evaluating attitudes towards digital mental health applications, factors that influence clinician prescribing of digital mental health applications, and perceived barriers to the adoption of digital mental health applications in a digitally-naïve sample of clinicians and patients (i.e., not previously exposed to these mental health applications).
    • Creating a clinician guide for best practices in prescribing digital mental health applications that can be readily scaled-up, deployed, and tested in future work.
    The Kaiser Permanente and Johns Hopkins Medicine Research Collaboration Committee (RCC) Pilot Projects
    Role: Principal Investigator
  4. Development, Deployment, and Evaluation of a Pharmacist-Coordinated Appointment-Based Model for Medication Synchronization (ABMMS) for Patients Living with HIV and Chronic Comorbid Medical Conditions
     This research proposes to evaluate the overall value of an appointment-based model for medication synchronization (ABMMS) for patients living with HIV and chronic comorbid medical conditions within a large integrated health system by:
    • Assessing the impact of an ABMMS on change in medication adherence (i.e., proportion of days covered), select clinical outcomes (i.e., viral load, HbA1c, blood pressure), and healthcare utilization (i.e., cardiovascular-related ER visits, hospital admissions) where event rates permit.
    • Describing patient satisfaction with the ABMMS.
    • Evaluating the impact of a pharmacist-focused effort and activities on improving adherence, the identification and resolution of drug therapy problems, and select clinical processes and outcomes.
    • Describing the relationship between patient measurements of depression, health literacy, self-efficacy, general self-reported adherence medication use in order to identify opportunities to improve medication adherence.
    • Determining the functionality and utility of the KP.org patient portal to facilitate the coordination of medication refill ordering and their ability to impact adherence.
    Pfizer, Inc.
    Role: Principal Investigator